托西利祖马布未能降低严重COVID-19患者的死亡率:随机对照临床试验的结果
Mona Talaschian1, Maryam Akhtari2, Mahdi Mahmoudi3
1Department of Internal Medicine, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Dr.talaschian@gmail.com.
托西利祖马布并没有显著改善严重COVID-19患者的临床结果. 这种干白素-6 (IL-6) 抑制剂在随机试验中没有显示出对标准治疗的益处.
科学领域:
- 免疫学 免疫学 免疫学
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
背景情况:
- 严重的COVID-19与升高的IL-6水平有关.
- 调节IL-6活性是严重COVID-19的潜在治疗策略.
- 托西利祖马布向IL-6受体,旨在减少炎症.
研究的目的:
- 评估托西利祖马布在治疗患有严重COVID-19的住院患者中的疗效.
- 为了确定托西利祖马布是否与标准护理 (SOC) 相比改善了临床结果.
主要方法:
- 进行了一项受控,随机,双盲临床试验.
- 40名住院的严重COVID-19患者接受了SOC加托西利祖马布或单独的SOC.
- 临床改善和出院是主要终点.
主要成果:
- 在托西利祖马布和SOC组 (70.6%与78.9%) 之间没有观察到恢复率的显著差异.
- 住院率在两组之间相似,危险比为0.83 (95% CI [0.39-1.78]).
- 托西利祖马布在严重的COVID-19的临床结果中没有显著改善.
结论:
- 托西利祖马布不是治疗严重COVID-19的有益药物.
- 该研究表明,用tocilizumab准IL-6并没有显著改变严重COVID-19的临床过程.
- 可能需要进一步的研究来探索其他IL-6调节策略或患者子组.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
